Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer

QUESTION: What are the benefits associated with the use of anti–epidermal growth factor receptor (anti-egfr) therapies in squamous cell carcinoma of the head and neck (hnscc)? Anti-egfr therapies of interest included cetuximab, gefitinib, lapatinib, zalutumumab, erlotinib, and panitumumab. PERSPECTI...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Cripps, C., Winquist, E., Devries, M.C., Stys–Norman, D., Gilbert, R.
Formato: Artigo
Idioma:Inglês
Publicado em: Multimed Inc. 2010
Assuntos:
Practice Guideline Series
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2880902/
https://ncbi.nlm.nih.gov/pubmed/20567625
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados